Financial Performance - Revenue reached $2.46 billion, a 4% increase compared to the previous year[47] - Adjusted Net Income was $783 million, representing a 10% year-over-year increase[47] - Adjusted Diluted EPS increased to $1.76, a 13% rise compared to the previous year[47] - The company is raising its 2025 revenue outlook to $9450 million - $9600 million[23] - The company is raising its 2025 adjusted net income outlook to $2825 million - $2875 million[23] - The company is raising its 2025 adjusted diluted EPS outlook to $630 - $640[23] Segment Performance - U S segment revenue totaled $1.4 billion, with 7% organic operational growth[20] - U S Companion Animal revenue reached $1.2 billion, a 9% year-over-year increase[20] - International segment revenue amounted to $1.1 billion, showing 9% organic operational growth[20] - International Livestock revenue grew by 10% on an organic operational basis[20] Product Performance - The Simparica franchise experienced 17% operational growth, with revenue reaching $448 million[29] - The Key Dermatology franchise grew by 11% operationally, with revenue reaching $460 million[34] - Livestock revenue increased by 6% on an organic operational basis, reaching $631 million (excluding MFA revenue)[44]